A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Israel, as Part of Local Clinical Practice

Sponsor
Novo Nordisk A/S
Study ID
NCT05443568
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Oral semaglutide — DRUG
    Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Study Details

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 8-10 months. Participants will be asked to complete a questionnaire about how they take their Rybelsus® tablets. Participants will complete this questionnaire during their normally scheduled visit with the study doctor.

Key Dates

Start date
Mar 9, 2023
Status verified
Oct 2025
Primary completion
Nov 16, 2024
Completion
Nov 16, 2024

Study Design

Enrollment
155 participants (actual)

Arms

  • Arm: Patients with type 2 diabetes
    Adult patients with type 2 diabetes and naïve to injectable glucose-lowering treatment.

Primary Outcome Measure

Change in HbA1c (Glycated haemoglobin) [ Time Frame: From baseline (week 0) to End of Study visit (V3) (week 34-44) ]

Related Studies